Results 271 to 280 of about 694,618 (329)

Immuno‐haemostatic dysregulation in heart failure with preserved ejection fraction

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex condition with partially unclear pathophysiology, in which systemic inflammation is a central contributor to changes in cardiac structure and function. The contribution of non‐traditional immune effectors—such as platelets and coagulation—remains underexplored in HFpEF ...
Giorgia D'Italia, Daniëlle M. Coenen, Titus P. Lemmens, Lloyd Brandts, Simone J. H. Wielders, Magdolna Nagy, Sanne G. J. Mourmans, Anouk Achten, Ahmad Al‐Abadi, Jerremy Weerts, Arantxa Barandiaran Aizpurua, Vanessa van Empel, Blanche Schroen, Judith M. E. M. Cosemans   +13 more
wiley   +1 more source

The Indispensable Role of Imaging in Catheter Ablation for Atrial Fibrillation. [PDF]

Acta Cardiol Sin
Lin CY, Chang SL.
europepmc   +1 more source

Prognostic value of longitudinal strain relative apical sparing in severe aortic stenosis patients undergoing TAVR

ESC Heart Failure, EarlyView.
Abstract Aims This study evaluated the prognostic value of the relative apical sparing pattern (RASP) of longitudinal strain (LS) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) and investigated whether its combination with pre‐procedural biomarkers enhances risk stratification.
Dan Liu, Kai Hu, Vera Schimpf, Victoria Sokalski, Friederike Hermann, Björn Daniel Lengenfelder, Georg Ertl, Stefan Frantz, Peter Nordbeck   +8 more
wiley   +1 more source

Surgical Methods and Devices for Atrial Fibrillation. [PDF]

Rev Cardiovasc Med
Yu Y, Jiang Q.
europepmc   +1 more source

Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification

ESC Heart Failure, EarlyView.
Abstract Clinical endpoint classification (CEC)—that is, evaluation of clinical events using pre‐defined criteria—is commonly conducted in clinical trial operations to ensure systematic and consistent assessment of endpoints needed to assess the intervention's safety and efficacy.
Veraprapas Kittipibul, Harriette G.C. Van Spall, William Schuyler Jones, Marat Fudim, Robert J. Mentz, Kevin Anstrom, Bertram Pitt, Patrice Desvigne‐Nickens, Jerome L. Fleg, Camilla Hage, Stefan James, Claes Held, Lars Lund, Adam DeVore   +13 more
wiley   +1 more source

Patient‐specific modifiers of survival benefit in cardiac resynchronization therapy ‐ A multicentre interaction analysis

ESC Heart Failure, EarlyView.
Abstract Background Cardiac resynchronization therapy (CRT) is a key intervention for patients with heart failure. The choice between a CRT with defibrillator therapy (CRT‐D) and a CRT with pacemaker (CRT‐P) is influenced by individual clinical characteristics.
Bert Vandenberk, Marius Brusselmans, Gabor Voros, Pieter Martens, Sebastian Ingelaere, Pascal Betschart, Jens‐Uwe Voigt, Matthias Dupont, Alexander Breitenstein, Jan Steffel, Rik Willems, Frank Ruschitzka, Wilfried Mullens, Sander Trenson, Stephan Winnik   +14 more
wiley   +1 more source

Concomitant Diabetes and Atrial Fibrillation: Epicardial Fat and Macrophage-Related Mechanisms. [PDF]

Diabetes Metab Res Rev
Al-Rubaye S, Rodríguez-Mañero M, Ramón González-Juanatey J, Eiras S.   +3 more
europepmc   +1 more source

Two‐year outcomes of a cardiac microcurrent device in chronic heart failure: A first‐in‐human pilot study

ESC Heart Failure, EarlyView.
Abstract Aims In heart failure patients, altered myocardial electrical fields linked to oedema may impair left ventricular function. While short‐term use of implanted microcurrent generators (C‐MIC) has shown promise, long‐term effects remain unclear.
Dragana B. Kosevic, Una Radak, Petar Vukovic, Jan D. Schmitto, Kersten Brandes, Peter Goettel, Hans‐Dirk Duengen, Elvis Tahirovic, Marija Zdravkovic, Johannes Mueller, Faouzi Kallel, Marat Fudim, Stefan D. Anker, Jesus Eduardo Rame, Miodrag Peric   +14 more
wiley   +1 more source